EsoBiotec develops in vivo engineered CAR-T cell therapies that empower the immune system to target and eliminate cancer cells, significantly reducing treatment costs and improving patient access. Their approach minimizes the risk of graft-versus-host disease and streamlines hospital processes, enhancing the overall patient experience in cancer care.
Funding
$9.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current CAR-T cell therapies require complex and expensive ex vivo engineering, limiting patient access and increasing the risk of graft-versus-host disease. Traditional methods also involve lengthy hospital stays and complicated logistical processes, adding to the overall cost and burden of cancer treatment.
Solution
EsoBiotec is developing in vivo CAR-T cell therapies that engineer a patient's own T cells directly within the body to target and eliminate cancer cells. This approach bypasses the need for external cell manipulation, reducing manufacturing costs and streamlining the treatment process. By leveraging the body's natural immune response, EsoBiotec's technology aims to minimize the risk of graft-versus-host disease and simplify hospital administration, ultimately improving patient outcomes and access to advanced cancer immunotherapies. The in vivo method accelerates treatment access, simplifies administration, and prevents host vs. graft rejection.
Target Audience
The primary target audience includes cancer patients who are candidates for CAR-T cell therapy, oncologists seeking more accessible and cost-effective treatment options, and hospitals aiming to streamline their cancer care processes.
Features
- In vivo CAR-T cell engineering, eliminating the need for ex vivo cell manipulation
- Targeted cancer cell elimination through engineered immune response
- Reduced risk of graft-versus-host disease compared to traditional CAR-T therapies
- Simplified treatment administration and hospital processes
- Potential for significant cost reduction in cancer treatment